Physician profile
Minesh B Pathak
NPI 1821299512
$13,907.92
in general payments reported to CMS, 2019-2025
25 companies · $2,819 in 2025
The $2,819 reported for 2025 was more than what 92% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,186 · 2020: $528 · 2021: $670 · 2022: $3,083 · 2023: $2,745 · 2024: $2,877 · 2025: $2,819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,996 · Education: $444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,996.47 |
| Education | $444.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,824.01 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,632.41 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals Lp | $1,417.37 | 2019-2024 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $1,212.92 | 2022-2025 | Filspari |
| Aurinia Pharma U.S., INC. | $1,197.53 | 2021-2025 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $1,137.28 | 2020-2025 | Acthar |
| Ardelyx, INC. | $1,034.05 | 2023-2025 | Ibsrela, Xphozah 30 Mg |
| Fresenius USA Marketing, INC. | $640.85 | 2019-2024 | Velphoro |
| Amgen INC. | $596.93 | 2019-2025 | Tavneos |
| Calliditas Therapeutics US INC. | $563.14 | 2022-2025 | Tarpeyo |
| Opko Pharmaceuticals, LLC | $412.02 | 2020-2025 | Rayaldee |
| Vifor Pharma, INC. | $399.88 | 2019-2025 | Veltassa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $398.30 | 2023-2025 | Jardiance |
| Medtronic, INC. | $250.21 | 2022 | |
| Novartis Pharmaceuticals Corporation | $180.11 | 2023-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $138.77 | 2022 | |
| Nxstage Medical, INC. | $135.61 | 2023 | Nxstage System One, Liberty Select Cycler |
| Mallinckrodt Enterprises LLC | $132.85 | 2019 | |
| Bard Peripheral Vascular, INC. | $118.96 | 2022 | |
| Glaxosmithkline, LLC. | $105.55 | 2021-2023 | Benlysta |
| Akebia Therapeutics INC | $103.78 | 2019-2024 | Vafseo |
| Lilly USA, LLC | $95.50 | 2025 | Jardiance |
| Vantive US Healthcare LLC | $76.83 | 2025 | Renal - Pd |
| Baxter Healthcare | $68.16 | 2019 | |
| Cormedix INC. | $34.90 | 2024 | Defencath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Minesh Pathak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.